<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556436</url>
  </required_header>
  <id_info>
    <org_study_id>YH25448-101</org_study_id>
    <nct_id>NCT03556436</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448</brief_title>
  <official_title>An Open-label, Single-dose Phase 1 Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 in Healthy Korean and Caucasian Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial is to evaluate the effect of ethnicity and food on the pharmacokinetics (how a
      drug is absorbed, metabolized, distributed and excreted; plasma drug concentration will be
      measured in this clinical trial) of YH25448, which Yuhan Corporation plans to develop as a
      therapeutic agent for Non-Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will be conducted in healthy Korean and Caucasian volunteers at Seoul
      National University Hospital (SNUH) Clinical Trial Center.

      It is expected to take approximately 39 days from the first dosing of Investigational Product
      until the final follow-up visit. It will be hospitalized twice for 9 nights and 10 days with
      21 days of interval, and one visit will be needed for safety evaluation between 14-17 days
      from the last dosing of the Investigational Product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>Area under the plasma concentration-time curve from zero to the time of the last quantitative concentration (AUC) of YH25448</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>Area under the plasma concentration-time curve from zero to the time of Maximum plasma concentration (Cmax) of YH25448</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>Area under the plasma concentration time curve from zero to infinity (AUC) of YH25448</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>Time to reach Cmax of YH25448</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>Terminal half life (t1/2) of YH25448</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>The apparent plasma clearance (CL/F) of YH25448</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of YH25448</measure>
    <time_frame>0-192 hrs</time_frame>
    <description>Apparent Volume of distribution of YH25448</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH25448 240mg single dose in korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH25448 240mg single dose in caucasian</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH25448 240mg</intervention_name>
    <description>period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>YH25448</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed of the investigational nature of this study and voluntarily agree to
             participate in this study.

          2. Subjects with BMI range of ≥18.5 kg/m2 and &lt; 30.0 kg/m2 and weighing ≥ 50 kg

          3. Subjects without congenital or chronic diseases within the last 3 years and without
             pathologic symptoms as determined by medical diagnosis

          4. Healthy Korean and Caucasian males who aged ≥ 19 and ≤ 55 years at the time of consent

        Exclusion Criteria:

          1. Clinically significant chronic infection (e.g. AIDS) or clinically significant medical
             or psychiatric illness

          2. Hypotension (SBP ≤ 90 mmHg or DBP ≤ 50 mmHg) or hypertension (SBP ≥ 150 mmHg or DBP ≥
             100 mmHg)

          3. A marked baseline prolongation of QTc greater than 450 msec by Bazett's formula

          4. Within 14 days prior to the first administration of investigational product, use of
             prescription drugs or herbal medication, or within 7 days use of any over-the-counter
             medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YH25448</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

